Targeting HER2 amplifications in metastatic colorectal cancer: searching for the most active combination therapy?
Mixed results from the the HERACLES-B, TRIUMPH and MOUNTAINEER trials
Closing the clinician–patient gap with patient-reported outcomes
PROs encourage patient-centred cancer care
‘Living’ anticancer medicines: has a new era started?
The benefits of adoptive T-cell therapy—where T-cells are given to induce a specific immune response—are moving closer to reality for patients with solid tumours
Two CDK 4/6 inhibitors prolong survival in HR+/HER2- breast cancer in pre- and post-menopausal women
Results from the MONARCH 2 and MONALEESA-3 trials
Immunotherapy fails to improve PFS and OS in relapsed mesothelioma
Results from the PROMISE-meso trial presented
Towards diagnosis of minimal residual disease
Liquid biopsies are fast making their mark as a diagnostic test for minimal residual disease (MRD), providing guidance on how to tailor treatment for early-stage cancers
Clinical benefits from antibody–drug conjugates are reported for bladder cancer
At ESMO 2019, early clinical data from two studies show the promise of this new generation of treatments although not yet practice-changing